MedTrace Logo

Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation

NCT00776633 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 614

Last updated 2016-08-30

No results posted yet for this study

Summary

The investigators hypothesize that reducing the duration of clopidogrel therapy from 6 months to 6 weeks after DES implantation is associated with improved clinical outcomes in patients on ASA and an oral anticoagulant.

Conditions

Interventions

DRUG

aspirin

6 weeks triple therapy with aspirin, clopidogrel and oral anticoagulation

DRUG

clopidogrel

6 months triple therapy with aspirin, clopidogrel and oral anticoagulation

DRUG

oral anticoagulation

Sponsors & Collaborators

  • Deutsches Herzzentrum Muenchen

    lead OTHER

Principal Investigators

  • Adnan Kastrati, MD · Deutsches Herzzentum München

  • Stefanie Schulz, MD · Deutsches Herzzentrum Muenchen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2013-12-31
Completion
2014-09-30

Countries

  • Denmark
  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00776633 on ClinicalTrials.gov